首页> 外文期刊>Journal of bacteriology >Functional Characterization by Genetic Complementation of aroB-Encoded Dehydroquinate Synthase from Mycobacterium tuberculosis H37Rv and Its Heterologous Expression and Purification
【24h】

Functional Characterization by Genetic Complementation of aroB-Encoded Dehydroquinate Synthase from Mycobacterium tuberculosis H37Rv and Its Heterologous Expression and Purification

机译:结核分枝杆菌H37Rv的aroB编码脱氢奎宁合酶的遗传互补功能表征及其异源表达和纯化

获取原文
           

摘要

The recent recrudescence of Mycobacterium tuberculosis infection and the emergence of multidrug-resistant strains have created an urgent need for new therapeutics against tuberculosis. The enzymes of the shikimate pathway are attractive drug targets because this route is absent in mammals and, in M. tuberculosis, it is essential for pathogen viability. This pathway leads to the biosynthesis of aromatic compounds, including aromatic amino acids, and it is found in plants, fungi, bacteria, and apicomplexan parasites. The aroB-encoded enzyme dehydroquinate synthase is the second enzyme of this pathway, and it catalyzes the cyclization of 3-deoxy-d-arabino-heptulosonate-7-phosphate in 3-dehydroquinate. Here we describe the PCR amplification and cloning of the aroB gene and the overexpression and purification of its product, dehydroquinate synthase, to homogeneity. In order to probe where the recombinant dehydroquinate synthase was active, genetic complementation studies were performed. The Escherichia coli AB2847 mutant was used to demonstrate that the plasmid construction was able to repair the mutants, allowing them to grow in minimal medium devoid of aromatic compound supplementation. In addition, homogeneous recombinant M. tuberculosis dehydroquinate synthase was active in the absence of other enzymes, showing that it is homomeric. These results will support the structural studies with M. tuberculosis dehydroquinate synthase that are essential for the rational design of antimycobacterial agents.
机译:结核分枝杆菌感染的近来复发和多重耐药菌株的出现,迫切需要针对结核病的新疗法。 iki草酸酯途径的酶是有吸引力的药物靶标,因为该途径在哺乳动物和 M中不存在。结核,对于病原体的生存至关重要。该途径导致包括芳族氨基酸在内的芳族化合物的生物合成,并且在植物,真菌,细菌和apicomplexan寄生虫中被发现。 aroB 编码的酶脱氢奎宁酸合酶是该途径的第二种酶,它催化3-脱氧-d- 阿拉伯糖-庚二磺酸酯7-磷酸盐在3中的环化。 -脱氢奎宁酸盐。在这里,我们描述了 aroB 基因的PCR扩增和克隆以及其产物脱氢奎宁酸合酶的过表达和纯化,使其达到同质。为了探测重组脱氢奎宁合酶在哪里有活性,进行了遗传互补研究。使用大肠杆菌 AB2847突变体来证明质粒构建能够修复该突变体,从而使其在没有添加芳香族化合物的基本培养基中即可生长。另外,均质重组 M。在没有其他酶的情况下,结核脱氢奎宁合酶是有活性的,表明它是同源的。这些结果将支持 M的结构研究。结核脱氢奎宁合成酶是合理设计抗分枝杆菌药物必不可少的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号